180 related articles for article (PubMed ID: 35945130)
1. Antibiotics and outcomes of CF pulmonary exacerbations in children infected with MRSA and Pseudomonas aeruginosa.
Cogen JD; Hall M; Faino AV; Ambroggio L; Blaschke AJ; Brogan TV; Cotter JM; Gibson RL; Grijalva CG; Hersh AL; Lipsett SC; Shah SS; Shapiro DJ; Neuman MI; Gerber JS
J Cyst Fibros; 2023 Mar; 22(2):313-319. PubMed ID: 35945130
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes of Antipseudomonal versus Other Antibiotics among Children with Cystic Fibrosis without
Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Nichols DP; Rosenfeld M; Kronman MP
Ann Am Thorac Soc; 2022 Aug; 19(8):1320-1327. PubMed ID: 35289740
[No Abstract] [Full Text] [Related]
3. Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nichols DP; Rosenfeld M; Gibson RL
Clin Infect Dis; 2021 Nov; 73(9):1589-1596. PubMed ID: 34100912
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic Regimen Changes during Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment.
Cogen JD; Sanders DB; Slaven JE; Faino AV; Somayaji R; Gibson RL; Hoffman LR; Ren CL
Ann Am Thorac Soc; 2023 Sep; 20(9):1293-1298. PubMed ID: 37327485
[No Abstract] [Full Text] [Related]
5. Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
Davis CS; Faino AV; Onchiri F; Gibson RL; Merjaneh L; Ramsey BW; Rosenfeld M; Cogen JD
Ann Am Thorac Soc; 2023 Jan; 20(1):75-82. PubMed ID: 36044723
[No Abstract] [Full Text] [Related]
6. Association of Intensity of Antipseudomonal Antibiotic Therapy With Risk of Treatment-Emergent Organisms in Children With Cystic Fibrosis and Newly Acquired Pseudomonas Aeruginosa.
Cogen JD; Onchiri FM; Hamblett NM; Gibson RL; Morgan WJ; Rosenfeld M
Clin Infect Dis; 2021 Sep; 73(6):987-993. PubMed ID: 33693586
[TBL] [Abstract][Full Text] [Related]
7. Antipseudomonal treatment decisions during CF exacerbation management.
VanDevanter DR; West NE; Sanders DB; Skalland M; Goss CH; Flume PA; Heltshe SL
J Cyst Fibros; 2022 Sep; 21(5):753-758. PubMed ID: 35466039
[TBL] [Abstract][Full Text] [Related]
8. Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response.
Lam JC; Somayaji R; Surette MG; Rabin HR; Parkins MD
BMC Infect Dis; 2015 Mar; 15():145. PubMed ID: 25887462
[TBL] [Abstract][Full Text] [Related]
9. Association between Staphylococcus aureus alone or combined with Pseudomonas aeruginosa and the clinical condition of patients with cystic fibrosis.
Hubert D; Réglier-Poupet H; Sermet-Gaudelus I; Ferroni A; Le Bourgeois M; Burgel PR; Serreau R; Dusser D; Poyart C; Coste J
J Cyst Fibros; 2013 Sep; 12(5):497-503. PubMed ID: 23291443
[TBL] [Abstract][Full Text] [Related]
10. Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations.
Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nelson M; Nichols DP; Rosenfeld M; VanDevanter DR; Gibson RL
Ann Am Thorac Soc; 2020 Dec; 17(12):1590-1598. PubMed ID: 32726564
[No Abstract] [Full Text] [Related]
11. Polymicrobial infections and antibiotic treatment patterns for cystic fibrosis pulmonary exacerbations.
Faino AV; Hoffman LR; Gibson RL; Kronman MP; Nichols DP; Rosenfeld M; Cogen JD
J Cyst Fibros; 2023 Jul; 22(4):630-635. PubMed ID: 36849332
[TBL] [Abstract][Full Text] [Related]
12. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
Sanders DB; Solomon GM; Beckett VV; West NE; Daines CL; Heltshe SL; VanDevanter DR; Spahr JE; Gibson RL; Nick JA; Marshall BC; Flume PA; Goss CH;
J Cyst Fibros; 2017 Sep; 16(5):592-599. PubMed ID: 28460885
[TBL] [Abstract][Full Text] [Related]
13. Comparison of intravenous and non-intravenous antibiotic regimens in eradication of P. aeruginosa and MRSA in cystic fibrosis.
Mursaloglu HH; Akın C; Yılmaz Yeğit C; Ergenekon AP; Suzer Uzunoglu B; Taştan G; Gökdemir Y; Erdem Eralp E; Karahasan Yağcı A; Karakoç F; Karadağ B
Pediatr Pulmonol; 2021 Dec; 56(12):3745-3751. PubMed ID: 34436829
[TBL] [Abstract][Full Text] [Related]
14. Multicenter Observational Study on Factors and Outcomes Associated with Various Methicillin-Resistant Staphylococcus aureus Types in Children with Cystic Fibrosis.
Muhlebach MS; Heltshe SL; Popowitch EB; Miller MB; Thompson V; Kloster M; Ferkol T; Hoover WC; Schechter MS; Saiman L;
Ann Am Thorac Soc; 2015 Jun; 12(6):864-71. PubMed ID: 25745825
[TBL] [Abstract][Full Text] [Related]
15. Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment.
Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Kronman MP; Rosenfeld M; Nichols DP
Ann Am Thorac Soc; 2021 Feb; 18(2):266-272. PubMed ID: 32810412
[No Abstract] [Full Text] [Related]
16. Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT.
Langton Hewer SC; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Sutton L; Clayton D; Arch B; Tanajewski Ł; Berdunov V; Williamson PR
Health Technol Assess; 2021 Nov; 25(65):1-128. PubMed ID: 34806975
[TBL] [Abstract][Full Text] [Related]
17. A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study.
Maliniak ML; Stecenko AA; McCarty NA
J Cyst Fibros; 2016 May; 15(3):350-6. PubMed ID: 26610860
[TBL] [Abstract][Full Text] [Related]
18. Utilization of antibiotics for methicillin-resistant Staphylococcus aureus infection in cystic fibrosis.
Zobell JT; Epps KL; Young DC; Montague M; Olson J; Ampofo K; Chin MJ; Marshall BC; Dasenbrook E
Pediatr Pulmonol; 2015 Jun; 50(6):552-9. PubMed ID: 25559432
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic duration and changes in FEV
Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
[TBL] [Abstract][Full Text] [Related]
20. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2015 Nov; (11):CD006961. PubMed ID: 26522473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
